Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
about
Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesPI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent.Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival.The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent.Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.The role of the hippo pathway in melanocytes and melanoma.Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell linesPIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
P2860
Q54931519-E197A6A7-77DF-43A5-B11B-F5F9A44F9E6BQ54931528-8AE7656E-CEAD-4319-BC8B-5219BBABFA10Q54931532-4068ADFC-42E6-42FA-96A8-5AE846A6603CQ54931561-BAEA6162-F98B-4A72-A4FA-BEBF2D1119A5Q54931562-45CBC276-DB79-4DE4-BAB1-78F59AB5B6B6Q54931566-6034A28C-D90A-486D-90F5-E71C73728293Q54931573-9AE26F99-B399-49E9-9F8C-3DF1DB69C379Q54931576-3B5D3CD1-A706-46D8-B1E0-325A3064FCBDQ54931577-8BBC3DCE-9A73-43C9-845C-4935BCE19C1DQ54931580-24E373EB-E6B4-44CF-B158-EF70EDFD529CQ54931587-8E61FD93-5C70-443A-B41B-6C914B1FE0B0Q54931595-69704624-4808-40CE-842F-55AAA3A79365
P1343
Q28542662-9BA1E5EC-59D6-43EC-BB7C-F13FC8D89F98Q35060792-3BDE19E9-F95A-4071-8601-A4E6E4C5B919Q35163699-75C48460-9418-4CE4-BE08-9DC7DAE81C9DQ35746524-7E63B86F-B6B4-4A93-8639-4E0A0CC6B33AQ37384015-72233DDA-FDC9-4B76-BCCE-E85B82AB1301Q37466867-2C87D9CD-B7BC-45EE-8B64-E50AD13C6412Q38983353-9840A2B3-852E-4815-913C-66CC8213553CQ39095954-48A4EBB5-525C-4241-8023-0F49A217CD4CQ39434922-CC31688D-E048-4AB9-860E-447692D4AD89Q40492746-509479F2-5320-4A2C-8551-B7D5C5AFBCDAQ40748577-95286DCF-917C-4AE8-B03C-4F7C82DBCD8DQ41235107-18EC41E0-231E-45F4-AB6E-D0D4B1309D11Q46095420-30C78347-AEAD-42B9-8FB6-A30E6499FB47
P2860
Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Comparison of growth factor si ...... cytes and melanoma cell lines.
@ast
Comparison of growth factor si ...... cytes and melanoma cell lines.
@en
Comparison of growth factor si ...... cytes and melanoma cell lines.
@nl
type
label
Comparison of growth factor si ...... cytes and melanoma cell lines.
@ast
Comparison of growth factor si ...... cytes and melanoma cell lines.
@en
Comparison of growth factor si ...... cytes and melanoma cell lines.
@nl
prefLabel
Comparison of growth factor si ...... cytes and melanoma cell lines.
@ast
Comparison of growth factor si ...... cytes and melanoma cell lines.
@en
Comparison of growth factor si ...... cytes and melanoma cell lines.
@nl
P2093
P2860
P4510
P356
P1433
P1476
Comparison of growth factor si ...... cytes and melanoma cell lines.
@en
P2093
Andrew N Shelling
Bruce C Baguley
Clare Stones
Euphemia Leung
Graeme J Finlay
Ji Eun Kim
Peter R Shepherd
Wayne A Phillips
Wayne R Joseph
P2860
P2888
P356
10.1186/1471-2407-12-141
P407
P577
2012-04-04T00:00:00Z
P5875
P6179
1030406575